Stocks Health care TRDA
NASDAQ · Health careEntrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. brought in $4.7M of revenue over the twelve months to June 30, 2026, down 94.1% from a year earlier. It posted a net loss of $165.8M. In fiscal 2025 capital spending exceeded operating cash flow by $129.6M. At June 30, 2026 it held $99.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Entrada Therapeutics, Inc. does
Entrada Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRDA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $25.4M | -$143.8M | -$3.47 | -$129.6M |
| 2024 | $210.8M | $65.6M | $1.68 | -$44.7M |
| 2023 | $129M | -$6.7M | -$0.20 | $134.2M |
| 2022 | n/a | -$94.6M | -$3.02 | -$96.7M |
| 2021 | n/a | -$51.2M | -$8.16 | -$55.4M |
| 2021 | n/a | -$26.5M | -$24.00 | -$27.9M |
Latest SEC filings
What Entrada Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 10, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- June 10, 2026
- May 19, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
- April 29, 2026Additional proxy material DEFA14A
- April 24, 2026
Questions about TRDA
What does Entrada Therapeutics, Inc. do?
Entrada Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRDA.
Is Entrada Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $165.8M on revenue of $4.7M.
How much revenue does Entrada Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Entrada Therapeutics, Inc. reported revenue of $4.7M. That is 94.1% less than a year earlier.
When did Entrada Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from September 10, 2026.
Similar companies
Follow TRDA
Get an email when Entrada Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TRDA: get an email when it filesWhere the numbers come from
Financial figures are the values Entrada Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.